#VisualAbstract: Daratumumab-based therapies were associated with higher rates of sustained minimal residual disease negativity in patients with newly diagnosed multiple myeloma Feb 8, 2022 Author Mukuntha Subburayan View all posts
Create Post
Twitter/X Preview
Logout